Peng Zhihua, Zhan Hong, Shao Yijia, Xiong Yan, Zeng Lijin, Zhang Cong, Liu Zhihao, Huang Zhenhua, Su Huanxing, Yang Zhen
1Division of Emergency Medicine, Department of Emergency Intensive Care Unit, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080 China.
2Department of Cardiology, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080 Guangdong China.
Chin Med. 2020 Jan 22;15:8. doi: 10.1186/s13020-020-0286-1. eCollection 2020.
Atherosclerosis, the underlying cause of the majority of cardiovascular diseases, is a lipid-driven, inflammatory disease of the large arteries. Atherosclerotic cardiovascular disease (ASCVD) threatens human lives due to high morbidity and mortality. Many studies have demonstrated that atherosclerosis is accelerated via activation of the NLRP3 inflammasome. The NLRP3 inflammasome plays a critical role in the development of vascular inflammation and atherosclerosis. In atherosclerotic plaques, excessive generation of reactive oxygen species (ROS) activates the NLRP3 inflammasome. 13-Methylberberine (13-MB) is a newly synthesized compound used in traditional Chinese medicine that has outstanding antibacterial, antitumor, and antiobesity activities, especially anti-inflammatory activity. However, the role of 13-MB in atherosclerosis needs to be explored.
CCK-8 assays and flow cytometry were conducted to determine the cell viability and apoptotic profiles of human umbilical vein endothelial cells (HUVECs) treated with 13-MB. Carboxy-DCFH-DA and JC-10 assays were used to measure ROS and determine mitochondrial membrane potential. Western blot analysis was performed to investigate proteins that are associated with the NLRP3 inflammasome and autophagy. ELISA was used to detect and quantify inflammatory cytokines related to the NLRP3 inflammasome. Transfection and confocal microscopy were conducted to observe autophagy.
Pretreatment with 13-MB markedly reduced cytotoxicity and apoptosis, as well as intracellular ROS production, in HO-induced HUVECs. Moreover, 13-MB showed a protective effect in maintaining mitochondrial membrane potential. 13-MB also suppressed NLRP3 inflammasome activation and promoted autophagy induction in HUVECs.
13-MB exerts cytoprotective effects in an HO-induced cell injury model by inhibiting NLRP3 inflammasome activation via autophagy induction in HUVECs. These anti-inflammatory and autophagy induction activities may provide valuable evidence for further investigating the potential role of 13-MB in atherosclerosis.
动脉粥样硬化是大多数心血管疾病的潜在病因,是一种由脂质驱动的大动脉炎症性疾病。动脉粥样硬化性心血管疾病(ASCVD)因其高发病率和死亡率威胁着人类生命。许多研究表明,通过激活NLRP3炎性小体可加速动脉粥样硬化。NLRP3炎性小体在血管炎症和动脉粥样硬化的发展中起关键作用。在动脉粥样硬化斑块中,活性氧(ROS)的过度产生会激活NLRP3炎性小体。13-甲基小檗碱(13-MB)是一种新合成的中药化合物,具有出色的抗菌、抗肿瘤和抗肥胖活性,尤其是抗炎活性。然而,13-MB在动脉粥样硬化中的作用有待探索。
进行CCK-8测定和流式细胞术,以确定用13-MB处理的人脐静脉内皮细胞(HUVECs)的细胞活力和凋亡情况。使用羧基-DCFH-DA和JC-10测定来测量ROS并确定线粒体膜电位。进行蛋白质印迹分析以研究与NLRP3炎性小体和自噬相关的蛋白质。使用酶联免疫吸附测定(ELISA)来检测和定量与NLRP3炎性小体相关的炎性细胞因子。进行转染和共聚焦显微镜观察自噬。
用13-MB预处理可显著降低HO诱导的HUVECs中的细胞毒性和凋亡,以及细胞内ROS的产生。此外,13-MB在维持线粒体膜电位方面显示出保护作用。13-MB还抑制HUVECs中NLRP3炎性小体的激活并促进自噬诱导。
13-MB通过在HUVECs中诱导自噬来抑制NLRP3炎性小体的激活,从而在HO诱导的细胞损伤模型中发挥细胞保护作用。这些抗炎和自噬诱导活性可能为进一步研究13-MB在动脉粥样硬化中的潜在作用提供有价值的证据。